Targacept Stock Hits New 52-Week Low (TRGT)

NEW YORK ( TheStreet) -- Targacept (Nasdaq: TRGT) hit a new 52-week low Monday as it is currently trading at $4.83, below its previous 52-week low of $4.87 with 88,855 shares traded as of 11:25 a.m. ET. Average volume has been 1.1 million shares over the past 30 days.

Targacept has a market cap of $194.6 million and is part of the health care sector and drugs industry. Shares are down 12% year to date as of the close of trading on Thursday.

Targacept, Inc., a biopharmaceutical company, engages in the discovery, design, and development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of diseases and disorders of the nervous system.

TheStreet Ratings rates Targacept as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow, generally disappointing historical performance in the stock itself and disappointing return on equity. You can view the full Targacept Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

If you liked this article you might like

3 Stocks Under $10 to Trade for Big Breakouts

5 Stocks Poised for Breakouts

Grading the Twitterverse's 2013 Biotech Stock Picks

5 Biotech Stocks Under $10 Making Big Moves

Three Cheers for Alkermes Running a Depression Study in the U.S. of A.